In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Meiji Seika Pharma Co. Ltd.

Division of Meiji Holdings Co. Ltd.
www.meiji-seika-pharma.co.jp/english/

Latest From Meiji Seika Pharma Co. Ltd.

Approval Positions Roxadustat As Japan HIF-PHI Pioneer

The latest batch of product approvals in Japan positions Astellas’s roxadustat as the pioneer in the country’s potentially large HIF-PH inhibitor market in anemia, while Takeda and Meiji Seika see other important approvals and the first biosimilar teriparatide receives a nod.

Japan Approvals

Japan Approves Biosimilar Teriparatide And Darbepoetin

Japan’s first biosimilar teriparatide has been approved for Mochida Pharmaceutical, while competition in the darbepoetin alfa arena looks set to step up following two recent authorizations.

Biosimilars Japan

No Panic At Newron Over Delayed Schizophrenia Drug Trial

Although the US FDA raised concerns about a rat toxicity trial, causing shares to slide, Italy's Newron believes the trial delay for schizophrenia therapy evenamide is just a blip.

Drug Safety Neurology

QIDP Roundup: Familiar Names Dominate 2019 Designations

US FDA's Qualified Infectious Disease Product program is growing slowly, but still growing.

Review Pathway Infectious Diseases
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Meiji Holdings Co. Ltd.
  • Senior Management
  • Daikichiro Kobayashi, PhD, Pres.
  • Contact Info
  • Meiji Seika Pharma Co. Ltd.
    Phone: (81) 3-3272-6511
    4-16 Kyobashi 2-chome, Chuo-ku
    Tokyo , 104-8002
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register